Induction of FLT3 in CML cells attenuates imatinib‐induced apoptosis, and FLT3 is associated with disease progression and prognosis (Kim et al., 2010). Here, FLT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.